B cell aplasia and hypogammaglobulinemia associated with levetiracetam

Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozdemir, Hulya, Sumer, Sua, Karabagli, Hakan, Akdemir, Gokhan, Caliskaner, A. Zafer, Artac, Hasibe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074184/
https://www.ncbi.nlm.nih.gov/pubmed/29313528
http://dx.doi.org/10.5144/0256-4947.2018.09.01.1430
_version_ 1783344350655152128
author Ozdemir, Hulya
Sumer, Sua
Karabagli, Hakan
Akdemir, Gokhan
Caliskaner, A. Zafer
Artac, Hasibe
author_facet Ozdemir, Hulya
Sumer, Sua
Karabagli, Hakan
Akdemir, Gokhan
Caliskaner, A. Zafer
Artac, Hasibe
author_sort Ozdemir, Hulya
collection PubMed
description Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After LEV discontinuation, the number of B cells gradually increased and reached normal levels within two months. This case suggests that monitoring of immunoglobulin levels and lymphocyte subsets analysis is important in patients treated with LEV, especially in cases of prolonged infections.
format Online
Article
Text
id pubmed-6074184
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher King Faisal Specialist Hospital and Research Centre
record_format MEDLINE/PubMed
spelling pubmed-60741842018-09-21 B cell aplasia and hypogammaglobulinemia associated with levetiracetam Ozdemir, Hulya Sumer, Sua Karabagli, Hakan Akdemir, Gokhan Caliskaner, A. Zafer Artac, Hasibe Ann Saudi Med Case Report Levetiracetam (LEV) is a second-generation antiepileptic drug approved for the treatment of several types of epilepsy. We report a 45-year-old female who developed hypogammaglobulinemia and B cell aplasia during LEV treatment. The Naranjo probability score for an adverse drug reaction was 6. After LEV discontinuation, the number of B cells gradually increased and reached normal levels within two months. This case suggests that monitoring of immunoglobulin levels and lymphocyte subsets analysis is important in patients treated with LEV, especially in cases of prolonged infections. King Faisal Specialist Hospital and Research Centre 2018 /pmc/articles/PMC6074184/ /pubmed/29313528 http://dx.doi.org/10.5144/0256-4947.2018.09.01.1430 Text en Copyright © 2018, Annals of Saudi Medicine This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Case Report
Ozdemir, Hulya
Sumer, Sua
Karabagli, Hakan
Akdemir, Gokhan
Caliskaner, A. Zafer
Artac, Hasibe
B cell aplasia and hypogammaglobulinemia associated with levetiracetam
title B cell aplasia and hypogammaglobulinemia associated with levetiracetam
title_full B cell aplasia and hypogammaglobulinemia associated with levetiracetam
title_fullStr B cell aplasia and hypogammaglobulinemia associated with levetiracetam
title_full_unstemmed B cell aplasia and hypogammaglobulinemia associated with levetiracetam
title_short B cell aplasia and hypogammaglobulinemia associated with levetiracetam
title_sort b cell aplasia and hypogammaglobulinemia associated with levetiracetam
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074184/
https://www.ncbi.nlm.nih.gov/pubmed/29313528
http://dx.doi.org/10.5144/0256-4947.2018.09.01.1430
work_keys_str_mv AT ozdemirhulya bcellaplasiaandhypogammaglobulinemiaassociatedwithlevetiracetam
AT sumersua bcellaplasiaandhypogammaglobulinemiaassociatedwithlevetiracetam
AT karabaglihakan bcellaplasiaandhypogammaglobulinemiaassociatedwithlevetiracetam
AT akdemirgokhan bcellaplasiaandhypogammaglobulinemiaassociatedwithlevetiracetam
AT caliskanerazafer bcellaplasiaandhypogammaglobulinemiaassociatedwithlevetiracetam
AT artachasibe bcellaplasiaandhypogammaglobulinemiaassociatedwithlevetiracetam

Ejemplares similares